Startup profile for Calytrix Bio: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Calytrix Bio funding, valuation and investors

Preclinical biotech developing mutant-CALR-targeting antibodies for myeloproliferative neoplasms; agreed to be acquired by Lilly.

Verified company research · funding, investors and latest developments

Keep track of Calytrix Bio

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A (amount undisclosed)

Amount not disclosed · Date not disclosed

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

Stage not recorded · Wellesley Hills, Massachusetts, United States

Investors in latest funding

Lead: J.P. Morgan Life Sciences Private Capital , Westlake BioPartners

Sources: latest funding · prnewswire.com Last verified: 2026-11-16

Overview

Calytrix Bio is a Wellesley Hills, Massachusetts biotechnology company founded in 2025 by J.P. Morgan Life Sciences Private Capital. It develops a biparatopic investigational antibody designed to target both common Type 1 and Type 2 variants of mutant calreticulin (mCALR), a molecular driver of some essential thrombocythemia and myelofibrosis cases.

On November 16, 2026 it announced a definitive agreement to be acquired by Eli Lilly for up to $1.5B cash, combining an undisclosed upfront payment and additional payments contingent on clinical and regulatory milestones. Neither the legal transaction close date nor future milestone attainability is known. Calytrix remains a private company pending verified closing.

Why Calytrix Bio is interesting

Its November 16, 2026 announced Lilly acquisition carries a maximum contingent consideration of $1.5B, not a disclosed upfront price or completed sale. The lead biparatopic antibody is preclinical; disease-modifying benefit has not been demonstrated in people.

Product & use cases

Research-stage therapy, not a marketed product. Investigational pathway: (1) identify patients with essential thrombocythemia or myelofibrosis whose disease is driven by Type 1 or Type 2 mutant CALR, based on appropriate molecular testing; (2) develop a biparatopic antibody intended to recognize mutant CALR while sparing normal tissue; (3) test mechanism, safety and exposure in preclinical systems; (4) seek authorization for human trials and measure safety and efficacy in staged trials; (5) only if positive data and required regulatory approvals emerge could physicians prescribe a resulting therapy. Calytrix has not reported clinical efficacy, dose, treatment schedule, pricing or commercial launch.

  • Investigational disease-modifying treatment research for mutant-CALR-positive essential thrombocythemia.
  • Investigational treatment research for mutant-CALR-positive myelofibrosis.

Key facts

  • Lilly acquisition announced Nov 16, 2026 for up to $1.5B; actual upfront cash amount undisclosed.
  • Milestone payments depend on future clinical/regulatory progress; the maximum is not guaranteed cash.
  • Calytrix lead mCALR biparatopic antibody remains preclinical, not an approved medicine.
  • Founded by J.P. Morgan Life Sciences Private Capital in 2025; Series A co-led with Westlake BioPartners and subsequent Series B led by Avoro Ventures, with round amounts not disclosed.

Funding history (newest first)

Series A (amount undisclosed)

  • J.P. Morgan Life Sciences Private Capital (lead)
  • Westlake BioPartners (lead)

Source: Read source · prnewswire.com

Series B (amount undisclosed)

  • Avoro Ventures (lead)

Source: Read source · prnewswire.com

Competitive landscape

Edge: The company hypothesizes its antibody could cover both major mutant-CALR classes and achieve disease modification. The breadth, comparative effectiveness, safety and clinical benefit are not yet demonstrated.

For diligence, distinguish preclinical target biology from a patient-ready drug. The unresolved questions are target selectivity, toxicity, effectiveness in Type 1/2 mutation subgroups, resistance, clinical trial design, and which future milestones release the contingent portion of the acquisition price. The absence of a reported upfront price prevents calculation of investor returns.

  • Current cytoreductive and symptom-directed MPN therapies incumbent

    Available clinical treatments manage blood counts/symptoms; not direct antibody equivalents.

  • Lilly/Ajax Therapeutics and other MPN investigational medicines adjacent

    Companies pursuing disease-modifying mechanisms with different targets or drug modalities.

  • Other mutant-CALR-targeting therapeutics direct

    Potential investigational alternatives; clinical comparability and approvals must be checked by molecular indication.

Notable stories

Market / IPO context

Editorial / static context — not a live quote.

FAQs about Calytrix Bio

Practical answers founders, operators, and investors typically search for.

No. The maximum potential amount includes undisclosed upfront cash plus contingent clinical and regulatory milestone payments.
A definitive agreement was announced November 16, 2026; closing was not confirmed in the original statement.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.